Clinical significance of MLH1/MSH2 for stage II/III sporadic colorectal cancer

doi:10.4251/wjgo.v11.i11.1065

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8008)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

428

WORD

250

HTML

4931

Figures (1-3)

242

Tables (1-4)

200

Sum=6051

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

648

Download

1309

Sum=1957

Nov 15, 2019 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastrointest Oncol. Nov 15, 2019; 11(11): 1065-1080
Published online Nov 15, 2019. doi: 10.4251/wjgo.v11.i11.1065

Full Size Figure Download Figure

Figure 2 Kaplan–Meier survival curves for patients with colorectal cancer, stratified according to expression of MLH1/MSH2. A: Overall survival of total colorectal cancer (CRC) patients classified as MLH1/MSH2-positive and MLH1/MSH2-negative subgroups; B: Overall survival of stage II CRC patients classified as MLH1/MSH2-positive and MLH1/MSH2-negative subgroups; C: Overall survival of stage III CRC patients classified as MLH1/MSH2-positive and MLH1/MSH2-negative subgroups; D: Overall survival of all adjuvant chemotherapy patients classified as MLH1/MSH2-positive and MLH1/MSH2-negative subgroups.

Citation: Wang SM, Jiang B, Deng Y, Huang SL, Fang MZ, Wang Y. Clinical significance of MLH1/MSH2 for stage II/III sporadic colorectal cancer. World J Gastrointest Oncol 2019; 11(11): 1065-1080
URL: https://www.wjgnet.com/1948-5204/full/v11/i11/1065.htm
DOI: https://dx.doi.org/10.4251/wjgo.v11.i11.1065